Riskpilot← Back to searchSign inGet full accessDisruptive Bio Trading ApS
APSActiveCVR 41532580Skyttevænget 9Non-specialised wholesale trade · NACE 4690Est. 20204 employeeswww.disruptivebiotrading.com
Revenue 2025
DKK 8M
+59% vs 2024
EBITDA margin
65.0%
+129% vs 2024
Equity ratio
35.6%
Financial strength
Net profit 2025
DKK 3,8M
+154% vs 2024
| Revenue | DKK 8M | +59% |
| EBITDA | DKK 5,2M | +129% |
| Net profit | DKK 3,8M | +154% |
| Total assets | DKK 11,5M | +36% |
| Equity | DKK 4,1M | +164% |
| Employees | 4 | — |
Legal name
Disruptive Bio Trading ApS
CVR number
41532580
Legal form
Anpartsselskab
NACE code
4690 · Non-specialised wholesale trade
Founded
14. juli 2020
Share capital
DKK 40.000
Employees
4 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at udøve virksomhed med handel og service samt aktiviteter i tilknytning hertil.
Address
Skyttevænget 9
Phone
+4593933630
Email
info@disruptivebiotrading.com
Website
www.disruptivebiotrading.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 57.403 | 100.000 | 31.874 | 5.024 | 7.991 |
| Staff expenses | -1.719 | -4.441 | -3.444 | -2.758 | -2.798 |
| EBITDA | 1.296 | 10.446 | 552 | 2.266 | 5.193 |
| Depreciation & amort. | -1 | -9 | -16 | -43 | -43 |
| EBIT | 1.295 | 10.437 | 536 | 2.223 | 5.149 |
| Net financials | -60 | -196 | -105 | -294 | -259 |
| Profit before tax | 1.235 | 10.241 | 431 | 1.929 | 4.890 |
| Tax | 274 | 2.267 | 107 | 430 | 1.076 |
| Net profit | 961 | 7.974 | 324 | 1.499 | 3.814 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 9.043 | 18.884 | 7.694 | 8.444 | 11.464 |
| Equity | 1.001 | 8.774 | 1.098 | 1.547 | 4.086 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 8.040 | 10.099 | 6.573 | 6.871 | 7.355 |
| Total debt | 8.040 | 10.099 | 6.573 | 6.871 | 7.355 |
EBITDA margin
65.0%
This company
15.8%
Market median
+311% vs market
20212025
Equity ratio
35.6%
This company
38.2%
Market median
+7% vs market
20212025
Return on equity
93.3%
This company
18.4%
Market median
+407% vs market
20212025
Net profit margin
47.7%
This company
8.1%
Market median
+489% vs market
20212025
Asset turnover
0.70×
This company
1.12×
Market median
-38% vs market
20212025
Debt / equity
1.81×
This company
0.62×
Market median
-192% vs market
20212025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2020-07-14 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
NS Management | Management | 2020 |
CL Founder | Founder | 2020 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 66.67–89.99% | 66.67–89.99% | 2024 | |
| Company | 10–14.99% | 10–14.99% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Lily Holding ApS
Disruptive Bio Trading ApS Board members of Disruptive Bio Trading ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Nicki Sol Leander Soto | Management | 0 companies |
| Christian Leander | Founder | 0 companies |